Retinal detachment: a prognostic factor analysis by Mafalda Maria Laracho de Seabra
2013/2014 
Mafalda Maria Laracho de Seabra 
Retinal detachment: a prognostic 
factor analysis 
março, 2014 
Mestrado Integrado em Medicina 
 
Área: Oftalmologia 
 
Trabalho efetuado sob a Orientação de: 
Dr. Manuel Alberto de Almeida e Sousa Falcão 
 
Trabalho organizado de acordo com as normas da revista: 
European Journal of Ophtalmology 
Mafalda Maria Laracho de Seabra 
Retinal detachment: a prognostic 
factor analysis 
março, 2014 


1 
 
RETINAL DETACHMENT: A PROGNOSTIC FACTOR ANALYSIS 
 
Prognostic factors in retinal detachment 
 
 
Mafalda Seabra, Manuel Falcão MD 
 
Department of Sense Organs, Faculty of Medicine of University of Porto 
Department of Ophthalmology of Hospital São João, Porto 
Corresponding author:  
Mafalda Seabra 
Alameda Hernani Monteiro  
4200-319 Porto 
Portugal 
Tel.: +351918432178. 
Email: mafseabra@hotmail.com 
 
Conflict of Interest - None of the authors has conflict of interest with the 
submission 
 
Financial support - No financial support was received for this submission 
  
2 
 
Abstract  
 
Purpose: To evaluate prognostic factors for retinal detachment. 
Methods: The patient’s medical records were reviewed and preoperative and 
intraoperative data analysed to ascertain an association with the outcomes: VA 
≤0,52 logMAR, VA ≤0,3 logMAR, VA ≤0,52 logMAR in eyes with macula-off and 
redetachment. 
Results: The difference in final visual acuity between the population of macula-
on and macula off was statistically significant (t-test: p <0,001). Mean 
postoperative VA was 0,41 ± 0,51 logMAR (n= 39; Snellen: 20/51) and 0,62 ± 
0,59 logMAR (n=109; Snellen: 20/83), respectively. Macula-off was a factor of 
poor prognosis (final VA worse than 0,3 logMAR). Mean time to surgery was 4 
days. The time to surgery did not affect final VA < 0,52 logMAR (p=0,694). 
Conclusions: The state of the macula only influenced the prognosis in a 
negative way when the final VA considered was 0,3 logMAR.  These situations 
can be managed as urgent procedures without the need of emergency 
interventions. In our series, time to surgery and pre-operative visual acuity were 
not prognostic factors.  
 
Keywords: retinal detachment, prognostic factors, macula 
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Introduction 
Retinal detachment occurs when the sensory retina and the retinal pigment 
epithelium separate (1,2,3).  
Three types of retinal detachment have been described: Rhegmatogenous, 
tractional and exsudative. Only the first type will be considered in this paper.  
The most common type (2,3,4), rhegmatogenous retinal detachment (RRD), is 
due to a retinal tear or break that may be instigated by trauma or posterior 
vitreous detachment (1). This break allows the accumulation of liquefied 
vitreous between the sensory retina and the retinal pigment epithelium. 
Posterior vitreous detachment is characteristic of the elderly, but there are other 
risk factors that can lead to this condition such as myopia, aphakia, focal retinal 
atrophy, trauma (1,4), family history and retinal detachment in the fellow eye (3). 
Affected individuals may be asymptomatic.  However, most people have 
symptoms: photopsia, floaters, visual field loss, diminished visual acuity (VA) or 
blurred vision (1,4). The diagnosis can be confirmed by ophthalmoscopy (3). 
If the tear is not repaired, the progressive accumulation of fluid between layers 
will have degenerative effects and eventually lead to blindness (3). 
A study undertaken in Portugal in 2010 estimated an incidence of 19 cases per 
100000 inhabitants (2). 
There are many treatment options. If there is just a tear in the retina, laser or 
cryotherapy may prevent the progression of fluid in the subretinal space 
preventing a complete retinal detachment. Nonetheless, if the retinal 
detachment is established, the first line treatment is surgical. Up to now the 
4 
 
preferred surgical technique lacks consensus (5) but several options are 
available, being retinopexy, scleral buckling and vitrectomy with internal 
tamponade the most frequently used surgical approaches (3).  
Up to now, the definition of prognostic factors still raises substantial discussion. 
Several definitions have been put forward, among which the most consensual 
ones are macula on/off (2,6,7,8,11), number of days until surgery 
(2,5,8,9,12,13), pre-operatory visual acuity (6,9) and age (9,10). 
Notwithstanding the results are yet to be widely accepted, particularly with 
regards to the number of days between the retinal detachment and surgery.  
This paper aims to analyse the prognostic factors in our population in the total 
number of retinal detachments and in patients with macula-off retinal 
detachments.  
Methods  
During a 29-month period, from January 2008 until May 2010, all patients with a 
retinal detachment who were admitted to Hospital de São João from the 
emergency department or referred by ophthalmologists, were enrolled in this 
study.  
Data was collected retrospectively from the medical records. Initially, all patients 
were included (n=265). Subsequently, those with retinal redetachment or retinal 
detachment other than rhegmatogenous were excluded.  
The following variables were analysed: age, sex, type of retinal detachment, 
affected eye, date of diagnosis, number of days from the appearance of the first 
symptoms until diagnosis, number of days until surgery, pre-operative visual 
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acuity (logMAR), myopia, phakia, simultaneous phacoemulsification with intra-
ocular lens implantation, number of quadrants involved, number of tears, 
location of the tears, presence of a giant tear, macula on/off, pre-operative 
proliferative vitreoretinopathy (PrePVR), vitreous haemorrhage, surgical 
technique (vitrectomy, scleral buckling or combined vitrectomy and scleral 
buckling), vitreous substitute, primary surgeon, pneumopexy used (cryotherapy 
or laser), final visual acuity at least 5 months after surgery (logMAR), and 
redetachment rate. 
A literature review of the studies focusing on prognostic factors of retinal 
detachment has been conducted in the MEDLINE database up to March 2014. 
Studies have been identified by using combinations of key words and through 
MeSH-based electronic searches. The reference lists of the relevant studies 
were thoroughly searched for additional studies.  
Statistical analysis was performed using SPSS version 22 (SPSS inc, Chicago, 
Illinois, USA). Descriptive statistics were obtained for all variables. Univariate 
analysis was performed to assess the association between the explanatory 
variables and the final outcome, using Mann-Whitney U test and Chi-square 
test. Logistic regression models were developed to identify factors that might 
influence the prognosis. Four outcomes were analysed: post-operative VA of 
0,52 logMAR or better, postoperative VA of 0,3 logMAR or better, redetachment 
during follow-up, and postoperative VA of 0,52 logMAR or better in the macula-
off population. The level of statistical significance was set at p<0,10.  
Results 
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The study included 245 eyes (Table I). The mean age of all patients was 60±14 
years (mean ± standard deviation) and there were 150 men (61,2%). A total of 
156 eyes were phakic (63,7%), 70 were pseudophakic (28,6%) and 7 were 
aphakic (2,9%). The macula was detached in 164 patients (66,9%), pre-
operative proliferative vitreoretinopathy was present in 12 patients (4,9%) 
(missing data: 17 (6,9%)) and vitreous haemorrhage in 18 patients (7,3%) 
(missing data: 15 (6,1%)).  
The mean time since the appearance of symptoms to diagnosis and to surgery 
was  19,08 ± 87,62 and 4,42 ± 4,47 days respectively. In the subpopulation with 
macula-on, the mean time to surgery was 4,67 ± 7,10 days while in those with 
macula-off it was 4,32 ± 2,64 days since diagnosis. 
The most common procedure performed was vitrectomy in 185 patients (75,5%) 
(missing data: 3 (1,2%)). As for the others, 51 (20,8%) had vitrectomy + scleral 
buckle and 6 (2,4%) performed scleral buckling. A vitreous substitute was used 
in 236 patients (96,3%) (missing data: 9 (3,7%)): gas tamponade (70,6%) and 
silicone oil tamponade (25,7%).  
Simultaneous cataract surgery and intra-ocular lens implantation was performed 
in 121 patients (49,4%) (missing data: 2 (0,8%)). Retinopexy was performed by 
cryotherapy in 10 patients (4,1%) and laser in 228 patients (93,1%). In 2.8% of 
cases, there was no information regarding retinopexy procedures. 
Pre-operative VA was documented in 188 patients (1,35 ± 0,88 logMAR). Post-
operative VA was recorded in 148 patients. The information regarding pre-
operative macular status was missing in 9 of these patients. Mean 
postoperative VA was 0,58 ± 0,59 logMAR (20/76). In the macula-on population, 
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the mean postoperative VA was 0,41 ± 0,51 logMAR (n= 39; Snellen: 20/51). 
Considering the macula-off population, mean postoperative visual acuity was 
0,62 ± 0,59 logMAR (n=109; Snellen: 20/83). This difference in visual acuity 
was statistically significant (t-test: p <0,001). 
Visual acuity was then dichotomized using two different outcomes: 0,3 logMAR 
(Snellen: 20/40) and 0,52 logMAR (Snellen: 20/66). From the 148 patients, 85 
(57,4%) had a visual acuity worse than 0,3 logMAR, whereas 47 (31,8%) had a 
visual acuity worse than 0,52 logMAR. 145 patients were considered when 
comparing the patients final VA and macular status. Among those patients with 
a final VA worse than 0,52 logMAR, 7 were macula-on eyes (17,9% of the total 
macula on eyes) and 38 were macula-off eyes (35,8% of macula-off eyes). As 
for those with a final VA worse than 0,3 logMAR, 16 (41%) were macula-on and 
66 (62,3%) were macula-off eyes. 
A univariate analysis to identify the factors that could be associated with a final 
visual acuity better than 0,52 logMAR was initially performed.  The following 
factors were selected to perform a logistic regression: preoperative VA, number 
of retinal tears, giant retinal tear, macula on/off, type of vitreous substitute and 
cryotherapy (the variables with p>0,2 were excluded). The logistic regression 
analysis revealed that multiple retinal tears (p=0,083) and gas tamponade 
(p=0,025) correlated statistically with the outcome (Table II). The involvement of 
the macula was not associated with the end result (p=0,807).  
To evaluate the independent predictors of poor outcome for a final visual acuity 
worse than 0,3 logMAR (Table III), the risk factors selected after the univariate 
analysis were: gender, time to surgery, number of quadrants involved, giant 
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retinal tear, macula on/off, surgical technique and type of vitreous substitute 
(the variables with p>0,2 were excluded). Two significant associations with final 
visual acuity were established with the logistic regression analysis: macula off 
(p=0,060) and use of silicone oil tamponade (p=0,054).  In this case, time to 
surgery did not show an association with the outcome (p=0,694). 
A univariate analysis was performed to select the variables for the logistic 
regression model in the subpopulation with macula-off, comparing those with a 
final VA better or worse than 0,52 logMAR. Time to surgery, number of retinal 
tears, vitreous haemorrhage and cryotherapy entered the logistic regression 
model (the variables with p>0,2 were excluded). Table IV shows that the 
presence of a vitreous haemorrhage (p=0,082), the use of silicone oil 
tamponade (p=0,054) and cryotherapy (p=0,071) are statistically significant 
predictors of a final visual acuity worse than 0,52 logMAR.  
Retinal redetachment occurred in 44 patients (18%). In this case, the variables 
selected for the logistic regression model by the univariate analysis were: 
gender, presence of PrePVR, surgical technique and cryotherapy (the variables 
with p>0,2 were excluded). With regards to this outcome (Table V), performing 
indentation plus vitrectomy (p=0,064), as well as female gender (p=0,024), were 
associated with the outcome (no redetachment).There was some evidence of 
association between redetachment and the presence of PrePVR (p=0,1).  
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Discussion 
Multiple surgical techniques can be used to approach retinal detachment. It is 
therefore very difficult to try and evaluate factors associated with a better 
prognosis, as several confounding variables may be present. 
Nonetheless, in this series, our aim was to ascertain the prognostic factors of 
rhegmatogenous retinal detachment. Two visual outcomes were defined: 0,3 
logMAR, usually considered driving vision, and 0,52 logMAR – reading vision.  
This series demonstrated that there are two factors associated with better 
prognosis in order to have a VA 0,52 logMAR or better. These are: multiple 
tears (ORs (95% (CI): 0,145 (0,016 – 1,288)) and use of gas tamponade (ORs 
(95% (CI): 0,241 (0,070 – 1,834)). On the other hand, the use of silicone oil 
tamponade was linked with bad prognosis if the outcome was 0,3 logMAR (ORs 
(95% (CI): 2,780 (0,938 – 7,856)). Time to surgery was not associated with 
either of these outcomes. 
Our series revealed that the type of vitreous substitute used (gas or silicone oil) 
can be an important prognostic factor. Silicone oil was a factor of poor 
prognosis for two of the outcomes analysed: final VA 0,3 and final VA 0,52 in 
the macula-off population. We must take into consideration that silicone oil is 
generally used when surgeons feel that there is a higher risk of redetachment 
and when a poorer prognosis is already expected. Therefore, it is likely that it is 
not the silicone oil that is a factor of poorer prognosis but rather that it is the 
tamponade that is used in patients that has a predisposition for a poorer 
prognosis. It is possible that silicone oil is a confounding variable. Nonetheless, 
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with this retrospective analysis, we were not able to determine which isolated 
variables led to the decision of using silicone oil as the internal tamponade.   
In our series, we found an association between multiple tears and having a final 
visual acuity better than 0.52 logMAR. However, when we raised the threshold 
for good prognosis to the level of 0.3 logMAR, the number of retinal tears was 
not associated with the final prognosis. Caution must be taken in interpreting 
these results. Visual acuity is not related with the peripheral retina and 
therefore, theoretically speaking, the number of tears should not interfere with 
visual acuity. Further studies that focus on the number of retinal tears may help 
to explain these results. 
Our findings showed that, although there was no association between visual 
acuity and macula using the cut-off of 0,52 logMAR (p=0,807), if we used the 
cut-off 0,3 logMAR, the association could be made (p=0,060). The reason is 
that many patients with macula-off retinal detachments can achieve visual 
acuities better than the cut-off we defined; as such, the probability of having at 
least reading vision after a retinal detachment is the same in people that 
present an attached or detached macula and it is greater than 50% in both 
studied populations. However, the patients that presented a macula-on retinal 
detachment had a better final visual acuity (0,41 ± 0,51 logMAR) compared with 
those with macula-off (0,62 ± 0,59 logMAR) (odds ratios (ORs) (95% confidence 
interval (CI): 2,286 (0,965 – 5,414)). These findings are consistent with other 
reports that have been published (7,11). Salicone (7) reported that 78% of 
patients with macula-off had final visual acuity worse than 0,3 logMAR 
compared with 28% in the macula-on group. We demonstrated that the 
probability of having a final visual acuity better than 0.3 logMAR was greater in 
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the patients with macula on, showing that an attached macula is an important 
prognostic factor for better final visual acuities. However, in our series, pre-
operative visual acuity was not associated with final visual acuity. We expect 
patients with a macula-on retinal detachment to have a better visual acuity at 
diagnosis and these two variables could have similar significance. However, 
there are patients with bullous retinal detachments with hidden macula-on 
detachments. This is probably why the status of the macula is a better 
prognostic factor than pre-operative visual acuity. 
When analysing the macula off population and using the endpoint of 0,52 
logMAR, we found three risk factors associated with poor prognosis: vitreous 
haemorrhage on diagnosis (ORs (95 %CI): 9,206 (0,752 – 112,742)), the use of 
silicone oil tamponade (ORs (95% (CI): 3,561 (0,980 – 12,940)) and 
cryotherapy (ORs (95% (CI): 5,908 (0,856 – 40,761)). However, since vitreous 
haemorrhage was present in 4 patients only and cryotherapy was performed in 
8 patients, these variables presented very wide confidence intervals, and 
therefore their results must be carefully interpreted.  
Focusing on the group of patients with macula-off, many authors have 
discussed the role of the time to surgery. This series showed that there is no 
association between the number of days until surgery (p=0,694) and the final 
outcome (using the endpoint: final visual acuity 0,3 logMAR). Other authors 
have reported the same findings (7-9, 12-13). However, the number of days in 
which this hypothesis can be verified is still under discussion. Thelen (13) 
reported that the surgery could be postponed for 3 days without compromising 
the prognosis, while Ross (8) reported a 7-day period, Hassan (9) a 10 day 
period and Doyle (13) a 30 day period. Our series showed that a 4-day wait 
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from diagnosis to surgery probably does not interfere with final visual acuity. 
These findings have clinical relevance as the decision to have surgery can be 
postponed for a short period of time until the best conditions for surgery can be 
optimized. Surgery for retinal detachment can be considered an urgent, but not 
an emergent, condition. 
We must emphasize that 242 of our patients had surgery within 2 weeks from 
the initial symptoms. We cannot infer results for patients that have had retinal 
detachments for more than two weeks. 
With resgards to redetachment rates, Foster (14) reported a 12% incidence of 
retinal detachment. In our series, 18% of cases redetached.  Performing scleral 
buckling along with a vitrectomy was associated with better prognosis (ORs (95 
%CI): 0,064 (0,003 – 1,487)), as well as female gender (ORs (95 %CI): 0,372 
(0,158 – 0,876)). These results differ from those of Kinori (15) who reported 
equal redetachment rates for cases treated solely with vitrectomy and for cases 
treated with vitrectomy and scleral buckle. Our series show that there may still 
be a role for a combined procedure in selected patients. Finding a protective 
effect in the female patients has not previously been reported. Although  genetic 
markers have recently been associated with proliferative vitreoretinopathy (16), 
gender has not been classically associated. We may hypothesise that these 
differences can be related to unknown hormonal factors that must be confirmed 
and investigated by further studies. 
Preoperatory proliferative vitreoretinopathy showed some degree of association 
with retinal redetachment (p=0,1; ORs (95% (CI): 3,083 (0,806 – 11,799)). 
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Nevertheless, only 12 patients (4,9%) presented with this condition rendering 
the variable a poor estimate.  
Our study has limitations. The major weakness is the retrospective nature of the 
study that used clinical records of regular clinical practice that lacks important 
data, making statistical analysis challenging. As far as visual acuity is 
concerned, this variable was not evaluated at the same post-operative stage. 
The range varies from five to 24 months. It has been suggested that visual 
acuity continues to improve for a period of up to 5 years (17), and this may limit 
the extrapolation of the results.   
Conversely, we have a large number of patients, which allows us to draw some 
conclusions.  
The majority of macula-on and macula-off patients present a visual acuity better 
than 0.52 logMAR. Nevertheless, having a macula-on increases the probability 
of having a visual acuity better than 0.3 logMAR. Furthermore, those patients 
with macula off can obtain reading vision in the majority of cases and surgery 
can be postponed for some days without compromising the results. Lastly. there 
might still be a role for combined vitrectomy and scleral buckling for retinal 
detachments for the prevention of redetachment. 
 
 
 
 
14 
 
1. Das T. Guidelines for the management of rhegmatogenous retinal 
detachment. Indian J Ophtalmol 1993; 41:37-40 
2. Gil Calvão-Santos. Epidemiologia do Descolamento da Retina na nossa 
Área de Actuação. Oftalmologia – Vol.34; pp.315-320 
3. John I. Lane. Retinal Detachment: Imaging of Surgical Treatments and 
Complications. RadioGraphics 2003; 23: 983-994 
4. Ray F. Gariano. Evaluation and Management of Suspected Retinal 
Detachment. American Family Physician 2004; volume 69, number 7: 
1691-1698 
5. Peter Walker. Retinal Detachment Surgeries. The Dilemma Between 
Personal Experience and Clinical Trials. Expert Ver Ophtalmol. 
2012;7(5):441-447 
6. Charles C. Wykoff. Fovea-Sparing Retinal Detachments: Time to Surgery 
and Visual Outcomes. American Journal of Ophtalmology 2010: 205-210 
7. Alberto Salicone. Visual Recovery after Scleral Buckling Procedure for 
Retinal Detachment. American Academy of Ophtalmmatology. 1734-
1742 
8. William H. Ross. Visual Recovery in Macula-off Rhegmatogenous Retinal 
Detachments. Ophtalmology, Volume 105, Number 11:2149-2153 
9. Tarek S. Hassan. The Effect of Duration of Macular  Detachment on 
Results after Scleral Buckle Repair of Primary, Macula-off Retinal 
Detachments. American Academy of Ophtalmology 2002: 146-151 
10. Otacílio de Oliveira Maia Junior. Descolamento regmatogéneo de retina: 
avaliação pós-operatória da mácula. Arq Bras Oftalmol. 2007;70(6);996-
1000. 
15 
 
11. del’OMO. Short-time prone posturing is well-tolerated and reduces the 
rate of unintentional retinal displacement in elderly patients operated o 
for retinal detachment. BMC Surgery 2013, 13(Suppl 2):S55.  
12. Ulrich Thelen. Outcome of surgery after macula-off retinal detachment – 
results from MUSTARD, one of the largest databases in Europe. Acta 
Ophtalmologica. 2012: 90: 481-486.  
13. E. Doyle. How effective is macula-off retinal detachment surgery. Might 
good outcome be predicted? Eye (2007) 21, 534-540 
14. Robert E. Foster. Recurrent Retinal Detachment More than 1 Year after 
Reattachment. Ophtalmology Volume 109, Number 10, October 2002.  
15. Michael Kinori. Comparison of Pars Plana Vitrectomy With and Without 
Scleral Buckle for the repair of Primary Rhegmatogenous Retinal 
Detachment. American Journal of Ophtalmology Vol. 152, No.2, 2012 
16.  Salvador Pastor-Idoate, Irene Rodriguez-Hernández, Jimena Rojas, et 
al. The p53 Codon 72 Polymorphism (rs1042522) Is Associated with 
Proliferative Vitreoretinopathy. Ophtalmology 2013; 120:623-628 
17. Sung Dong Chang. Long-term Visual Recovery After Scleral Buckling 
Procedure of Rhegmatogenous Retinal Detachment Involving the 
Macula. Korean J Ophtalmol. Vol 13:20-26, 2000 
 
 
 
 
 
16 
 
Table I 
Characteristics of the sample  
Variables  Missing data 
n (%) 
Socio-demographic characteristics   
Age (years)  0 
Mean (SD) 60±14  
Gender, n (%)  0 
Male 150 (61,2%)  
Female 95 (38,8%)  
Time to diagnosis (days) 
(mean ± SD) 
19,08 ± 87,62 74 (30,2%) 
Time to surgery since diagnosis 
(days) 
(mean ± SD) 
4,42 ± 4,47 2 (0,8%) 
Preoperative VA logMAR 
(mean ± SD) 
1,35 ± 0,88 57 (23,3%) 
Refractive error, n (%)  85 (34,7%) 
Myopia < -6D 125 (51%)  
Myopia > -6D 35 (14,3%)  
Lens status, n (%)  12 (4,9%) 
Phakic 156 (63,7%)  
Pseudophakic 70 (28,6%)  
Aphakic 7 (2,7%)  
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RRD extent, n (%)  17 (6,9%) 
1 quadrant 48 (19,6%)  
2 quadrant 101 (41,2%)  
3 or 4 quadrant 79 (32,2%)  
Retinal tears, n (%)  30 (12,2%) 
None  24 (9,8%)  
One   110 (44,9%)  
Multiple  81 (33,1%)  
Giant retinal tear, n (%)  26 (10,6%) 
Yes  18 (7,3%)  
No  201 (82%)  
Macula, n (%)  9 (3,7%) 
On  72 (29,4%)  
Off  164 (66,9%)  
 
Abbreviations: VA – visual acuitity; D – diopters; RRD – Rhegmatogenous 
retinal detachment; SD – standard deviation 
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Table II 
Results of the logistic regression analysis for final visual acuity lower than 0,52 
logMAR.  
Risk Factors p value Odds ratio 95% CI 
Preoperative VA  0,154 1,873 0,791-4,433 
Retinal tears    
None   1.0 (referent)  
One   0,422 0,427 0,053-3,408 
Multiple  0,083 0,145 0,016-1,288 
Giant tear  0,231 2,878 0,510-16,228 
Macula on/off 0,807 1,230 0,233-6,494 
Gas Tamponade 0,025 0,241 0,070-0,834 
Cryotherapy 0,095 5,077 0,755-34,160 
 
Abbreviations: VA – visual acuity; CI – confidence intervals 
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Table III 
Results of the logistic regression analysis for final visual acuity lower than 0,3 
logMAR.  
Risk Factors p value Odds ratio 95% CI 
Gender, Female 0,398 1,409 0,637 – 3,121 
Time to surgery 0,694 1,034 0,874-1,225 
RDD extent    
1 quadrant  1.0 (referent)  
2 quadrant 0,435 1,438 0,578– 3,578 
3 or 4 quadrant 0,204 1,990 0,965- 5,760 
Macula on/off 0,060 2,286 0,965- 5,414 
Giant tear 0,130 3,137 0,714-13,790 
Scleral buckle + 
vitrectomy 
0,312 1,601 0,634-3,991 
Silicone oil 
Tamponade 
0,054 2,780 0,983-7,856 
  
Abbreviations: RDD - Rhegmatogenous retinal detachment; CI – confidence 
intervals 
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Table IV 
Results of the logistic regression analysis for final visual acuity < 0,52 logMAR 
in the macula-off population.    
Risk Factors p value Odds ratio 95% CI 
Time to diagnosis 0,761 1,004 0,977 – 1,033 
Vitreous haemorrhage  0,082 9,206 0,752 – 112,742 
Silicone oil 
Tamponade 
0,054 3,561 0,980 – 12,940 
Cryotherapy 0,071 5,908 0,856 – 40,761 
Retinal tears    
None   1.0 (referent)  
One   0,722 0,727 0,126-4,193 
Multiple  0,117 0,218 0,031-1,465 
 
Abbreviations: CI – confidence intervals 
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Table V 
Results of the logistic regression analysis for retinal redetachment  
Risk Factors p value Odds ratio 95% CI 
Gender, Female 0,024 0,372 0,158 – 0,876 
PrePVR 0,100 3,083 0,806 – 11,799 
Surgical technique    
Indentation  1.0 (referent)  
Vitrectomy 0,242 0,170 0,009 – 3,311 
Scleral buckle + 
vitrectomy 
0,087 0,064 0,003 – 1,487 
Vitreous substitute 0,981 0,996 0,728 – 1,363 
Cryotherapy 0,282 2,268 0,511 – 10,074 
 
Abbreviations: CI – confidence intervals; PrePVR - preoperatory proliferative 
vitreoretinopathy 
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